A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 460 (planned)
- Started
- Dec 29, 2023
- Main results expected
- Oct 28, 2027
- Fully finished
- Oct 28, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AEs)
Measured over: Up to 2 years and 1 month
Number of participants with serious adverse events (SAEs)
Measured over: Up to 2 years and 1 month
Number of participants with AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria
Measured over: Up to Day 28
Number of participants with AEs leading to death
Measured over: Up to 2 years and 1 month
Number of participants with AEs leading to discontinuation
Measured over: Up to 2 years and 1 month
Number of participants with a complete response rate (CRR) according to the Lugano response criteria for Non-Hodgkin Lymphoma by Investigator assessment
Measured over: Up to 2 years and 11 month
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06090539 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC